Tin tức & Cập nhật

Sustained benefits with ocrelizumab in relapsing-remitting MS
Sustained benefits with ocrelizumab in relapsing-remitting MS
19 May 2022 bởiRoshini Claire Anthony

Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.

Sustained benefits with ocrelizumab in relapsing-remitting MS
19 May 2022
How does IV edaravone fare for ALS in the real world?
How does IV edaravone fare for ALS in the real world?
10 May 2022
AChEIs and memantine cost-effective, offer improvements in AD
AChEIs and memantine cost-effective, offer improvements in AD
09 May 2022 bởiNatalia Reoutova

A systematic review and meta-analysis of Alzheimer’s disease (AD) therapies’ cost-effectiveness carried out by researchers from the Chinese University of Hong Kong (CUHK) identifies acetylcholinesterase inhibitors (AChEIs) and memantine as cost-effective and offering improvements in dementia-related symptoms.

AChEIs and memantine cost-effective, offer improvements in AD
09 May 2022